David Maggs
Algemeen Directeur bij Abvance Therapeutics, Inc.
Profiel
David Maggs has founded Abvance Therapeutics, Inc. in 2016, where he is currently the Chief Executive Officer.
He held the position of Director-Medical Research, Diabetes & Metabolism at Parke, Davis & Co. LLC from 1997 to 1999.
He was also the Vice President-Medical Affairs at Amylin Pharmaceuticals, Inc. He served as the Chief Medical Officer at GI Dynamics, Inc. from 2013 to 2015.
Dr. Maggs holds a doctorate degree from the University of London.
Actieve functies van David Maggs
| Bedrijven | Functie | Begin |
|---|---|---|
Abvance Therapeutics, Inc.
 Abvance Therapeutics, Inc. BiotechnologyHealth Technology Abvance Therapeutics, Inc. is a pharmaceutical company that aims to improve diabetes control and reduce the risk of hypoglycemia. The company is based in Reno, NV. The company's Abv100 platform is designed to replace rapid acting insulin and can be used by any patient type, including those with type 1 and type 2 diabetes who use injections or pumps. The platform protects against hypoglycemia, allowing for safer use of insulin and better control of diabetes, which can lead to improved long-term health outcomes. The company was founded in 2016 by Alan Cherrington, David Maggs, and Soumitra Ghosh. David Maggs has been the CEO since 2016. | Algemeen Directeur | 01-01-2016 |
Eerdere bekende functies van David Maggs
| Bedrijven | Functie | Einde |
|---|---|---|
| GI DYNAMICS, INC. | Hoofd Techniek/Wetenschap/O&O | 18-06-2015 |
| Parke, Davis & Co. LLC | Corporate Officer/Principal | 01-01-1999 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van David Maggs
| University of London | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
GI Dynamics, Inc.
 GI Dynamics, Inc. Medical SpecialtiesHealth Technology GI Dynamics, Inc. engages in the development and commercialization of a medical device system intended for treatment of patients with type 2 diabetes and reduction of obesity. Its pipeline product is EndoBarrier, an endoscopically delivered medical device intended to help restore healthy blood sugar levels and reduce weight. The company was founded by Andy Levine on March 24, 2003 and is headquartered in Boston, MA. | Health Technology |
| Parke, Davis & Co. LLC | |
Abvance Therapeutics, Inc.
Abvance Therapeutics, Inc. BiotechnologyHealth Technology Abvance Therapeutics, Inc. is a pharmaceutical company that aims to improve diabetes control and reduce the risk of hypoglycemia. The company is based in Reno, NV. The company's Abv100 platform is designed to replace rapid acting insulin and can be used by any patient type, including those with type 1 and type 2 diabetes who use injections or pumps. The platform protects against hypoglycemia, allowing for safer use of insulin and better control of diabetes, which can lead to improved long-term health outcomes. The company was founded in 2016 by Alan Cherrington, David Maggs, and Soumitra Ghosh. David Maggs has been the CEO since 2016. | Health Technology |
